L-arginine polymers inhibit the development of vein graft neointimal hyperplasia

Journal of Thoracic and Cardiovascular Surgery

Volumn 121, Issue 5, 2001, Pages 971-980

  Kown, Murray H ^a   Yamaguchi, Atsushi ^a   Jahncke, Christina L ^a   Miniati, Douglas ^a   Murata, Seiichiro ^a   Grunenfelder, Jurg ^a   Koransky, Mark L ^a   Rothbard, Jonathan B ^b   Robbins, Robert C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cellgate Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; NITRIC OXIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; JUGULAR VEIN; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RABBIT; VEIN GRAFT;

EID: 0035353695     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2001.112532     Document Type: Article

References (30)

1. Canver CC. Conduit options in coronary artery bypass surgery. Chest 1995;108:1150-5.
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5.065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
3. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation 1998;97:916-31.
4. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996;78:225-30.
5. Best PJ, Hasdai D, Sangiorgi G, Schwartz RS, Holmes DR, Simari RD, et al. Apoptosis: Basic concepts and implications in coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:14-22.
6. Hecker M, Catturuzza M, Wagner AH. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol 1999;32:9-16.
7. Wu G, Morris SMJ. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998;336:1-17.
8. Fulton GJ, Davies MG, Barber L, Gray JL, Svendsen E, Hagen PO. Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts. Eur J Vasc Endovasc Surg 1998;15:279-89.
9. Okazaki J, Komori K, Kawasaki K, Eguchi D, Ishida M, Sugimachi K. L-Arginine inhibits smooth muscle cell proliferation of vein graft intimal thickness in hypercholesterolemic rabbits, Cardiovasc Res 1997;36:429-36.
10. Davies MG, Dalen H, Kim JH, Barber L, Svendsen E, Hagen PO. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. J Surg Res 1995;59:35-42.
11. Mitchell D, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters ceils more efficiently than other polycationic homopolymers. J Pept Res 2000;56:318-25.
12. Hill CM, Liu A, Marshall KW, Mayer J, Jorgensen B, Yuan B, et al. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J Immunol 1994;152:2890-8.
13. Cohen J, Evans TJ, Spink J. Cytokine regulation of inducible nitric oxide synthase in vascular smooth muscle cells. Prog Clin Biol Res 1998;397:169-77.
14. von der L, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995;92:1137-41.
15. Shears LL, Kawaharada N, Tzeng E, Billiar TR, Watkins SC, Kovesdi I, et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997;100:2035-42.
16. Koide M, Kawahara Y, Nakayama I, Tsuda T, Yokoyama M. Cyclic AMP elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells: Synergism with the induction elicited by inflammatory cytokines. J Biol Chem 1993;268:24959-66.
17. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA. Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-72.
18. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89:2176-82.
19. Jeremy RW, McCarron H, Sullivan D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit: Response according to treatment duration, anatomic site, and sex. Circulation 1996;94:498-506.
20. Castillo L, Ajami A, Branch S, Chapman TE, Yu YM, Burke JF, et al. Plasma arginine kinetics in adult man: Response to an arginine-free diet. Metabolism 1994;43:114-22.
21. Southern LL, Baker DH. Performance and concentration of amino acids in plasma and urine of young pigs fed diets with excesses of either arginine or tysine. J Anim Sci 1982;55:857-66.
22. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995;92:5855-9.
23. Vires E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-17.
24. Efthymiadis A, Briggs LJ, Jans DA. The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties. J Biol Chem 1998;273:1623-8.
25. Uemura S, Fathman CG, Rothbard JB, Cooke, JP. Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia. Circulation 2000;702:2629-35.
26. Hansson GK, Geng YJ, Holm J, Hardhammar P, Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994;180:733-8.
27. Chester AH, Borland JA, Buttery LD, Mitchell JA, Cunningham DA, Hafizi S, et al. Induction of nitric oxide synthase in human vascular smooth muscle: Interactions between proinflammatory cytokines. Cardiovasc Res 1998;38:814-21.
28. Dusting GJ, Macdonald PS. Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med 1995;27:395-406.
29. Masini E, Salvemini D, Ndisang JF, Gai P, Berni L, Moncini M, et al. Cardioprotective activity of endogenous and exogenous nitric oxide on ischaemia reperfusion injury in isolated guinea pig hearts. Inflamm Res 1999;48:561-8.
30. Vinten-Johansen J, Sato H, Zhao ZQ. The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. Int J Cardiol 1995;50:273-81.